As 2026 begins, Java Burn reviews are once again climbing search results, not because of hype alone, but because ...
India is launching cheap weight-loss drugs — but Novo Nordisk is betting its brands will stay on top
Novo lost semaglutide patent protection in India, triggering generic launches. Indian drugmakers launched generic versions at lower prices. Novo cut prices and used partnerships to defend market share ...
Novo Nordisk lost its patent over semaglutide, which makes Wegovy and Ozempic, in India. That means the floodgates of generics opened and overnight the price of weight-loss drugs dropped by 80%. There ...
AI Quick Read MUMBAI: A day after semaglutide lost patent protection in India, top drugmakers including Dr Reddy’s, Sun Pharma, and Zydus Lifesciences launched generic versions priced 50-90% below the ...
India’s obesity drug market is on the cusp of a shake-up, with at least a dozen large drugmakers preparing to launch generic versions of Novo Nordisk’s blockbuster weight-loss drugs as soon as patent ...
HYDERABAD: A surge in the unsupervised use of popular diabetes and weight-loss drugs in Hyderabad has raised alarm among doctors, who warn that social media trends and peer influence are pushing many ...
The weight-loss world is on the brink of a major shake-up. Pharmaceutical companies in India will get the green light this weekend to start selling generic versions of Ozempic and Wegovy, with several ...
Come March 20, when the patent for Semaglutide expires, the Indian market is expected to see the launch of generic drugs from at least seven pharma companies, at costs ranging from one-third to ...
Merck KGaA forecast lackluster earnings in guidance that reflects generic competition for its multiple sclerosis blockbuster drug Mavenclad, but not the potential benefits from the US launch of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results